2026 Carleen Cullinane: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	61	11596	10681	319	308	206	10213

Overview

Carleen Cullinane is affiliated with the Peter MacCallum Cancer Centre in Australia and has focused their research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work encompasses significant contributions to Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging, Epidemiology, and Cancer Research.

The research topics addressed by Cullinane include:

Radiopharmaceutical Chemistry and Applications
Peptidase Inhibition and Analysis
Neuroendocrine Tumor Research Advances
Lung Cancer Research Studies
Cancer therapeutics and mechanisms
CAR-T cell therapy research
DNA Repair Mechanisms

Among their recent publications are the following papers:

"Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP," 2020, Scientific Reports
"Peptide Receptor Radionuclide Therapy with ⁶⁷Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model," 2020, Journal of Nuclear Medicine

Other notable papers in which they contributed as an author or co-author include:

"CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer," 2020, Nature Communications
"EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma," 2020, Journal of Investigative Dermatology
"The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer," 2020, British Journal of Cancer

Cullinane has collaborated frequently with other researchers, including:

Rodney J. Hicks
Jessica Van Zuylekom
Peter Roselt
Paul S. Donnelly
Grant A. McArthur

Their work has been published in several recurring venues, principally:

Journal of Medicinal Chemistry
Cancer Research
Nature Communications
Journal of Nuclear Medicine
Chemical Science

Best Publications

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Megan J Bywater;Gretchen Poortinga;Gretchen Poortinga;Elaine Sanij;Elaine Sanij;Nadine Hein

561
Citations
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Marian L. Burr;Marian L. Burr;Marian L. Burr;Christina E. Sparbier;Christina E. Sparbier;Kah Lok Chan;Kah Lok Chan;Yih-Chih Chan

475
Citations
Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study

Vanya D. Uzunova;Carleen Cullinane;Klaudia Brix;Werner M. Nau

424
Citations
UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas

Stephen Q. Wong;Kelly Waldeck;Ismael A. Vergara;Jan Schröder;Jan Schröder;Jan Schröder

317
Citations
Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation

David Shi Hao Liu;Cuong Phu Duong;Sue Haupt;Karen G Montgomery

299
Citations
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

Tiffany J. Parmenter;Margarete Kleinschmidt;Kathryn M. Kinross;Simon T. Bond

277
Citations
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Richard J. Young;Kelly Waldeck;Claire Martin;Jung H. Foo

240
Citations
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Kathryn M Kinross;Karen G Montgomery;Margarete Kleinschmidt;Paul Waring

234
Citations
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.

Elaine Sanij;Elaine Sanij;Katherine M. Hannan;Katherine M. Hannan;Jiachen Xuan;Jiachen Xuan;Shunfei Yan;Shunfei Yan

190
Citations
Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.

Timothy W. Failes;Carleen Cullinane;Connie I. Diakos;Natsuho Yamamoto

178
Citations
EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma

Benjamin Solomon;Jim Hagekyriakou;Melanie K Trivett;Steven A Stacker

164
Citations
Multi-nuclear platinum complexes encapsulated in cucurbit[n]uril as an approach to reduce toxicity in cancer treatment

Nial J. Wheate;Anthony I. Day;Rodney J. Blanch;Alan P. Arnold

151
Citations
Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

Gerald Reischl;Donna S Dorow;Carleen Cullinane;Andrew Katsifis

144
Citations
PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate

Brett M. Paterson;Peter Roselt;Delphine Denoyer;Carleen Cullinane;Carleen Cullinane

125
Citations
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

George H. Au-Yeung;George H. Au-Yeung;Franziska Lang;Walid J Azar;Chris Mitchell

124
Citations
An In vivo Tumor Model Exploiting Metabolic Response as a Biomarker for Targeted Drug Development

Carleen Cullinane;Donna S. Dorow;Maya Kansara;Nelly Conus

122
Citations
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Jennifer R Devlin;Katherine M Hannan;Katherine M Hannan;Nadine Hein;Nadine Hein;Carleen M Cullinane;Carleen M Cullinane

119
Citations
LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

Prue A Cowin;Joshy George;Joshy George;Sian Fereday;Elizabeth Loehrer

118
Citations
Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

Dariush Etemadmoghadam;George Au-Yeung;Meaghan Wall;Chris Mitchell

117
Citations
Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

Dariush Etemadmoghadam;Joshy George;Joshy George;Prue A. Cowin;Carleen Cullinane

117
Citations